Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well nivolumab works with the DA-REPOCH chemotherapy regimen
in treating patients with aggressive B-cell non-Hodgkin lymphoma. Immunotherapy with
monoclonal antibodies, such as nivolumab, may help the body?s immune system attack the
cancer, and may interfere with the ability of cancer cells to grow and spread. Drugs used in
chemotherapy, such as dose-adjusted rituximab, etoposide, prednisone, vincristine sulfate,
cyclophosphamide, and doxorubicin hydrochloride (DA-REPOCH), work in different ways to stop
the growth of cancer cells, either by killing the cells, by stopping them from dividing, or
by stopping them from spreading. Giving nivolumab with DA-REPOCH may work better in treating
patients with aggressive B-cell non-Hodgkin lymphoma.
Phase:
Phase 2
Details
Lead Sponsor:
David Bond, MD Kami Maddocks
Collaborators:
Bristol-Myers Squibb National Cancer Institute (NCI)